Top

International Journal of Clinical Oncology

Published in:

01-04-2017 | Original Article

Quality-of-life evaluation during platinum-based neoadjuvant chemotherapies for urothelial carcinoma

Authors: Ken Fukushi, Takuma Narita, Shingo Hatakeyama, Hayato Yamamoto, Osamu Soma, Teppei Matsumoto, Yuki Tobisawa, Tohru Yoneyama, Atsushi Imai, Takahiro Yoneyama, Yasuhiro Hashimoto, Takuya Koie, Chikara Ohyama

Published in: International Journal of Clinical Oncology | Issue 2/2017

Abstract

Background

Although quality of life (QOL) is one of the most important considerations in patients treated with anticancer therapies, desirable regimens for neoadjuvant chemotherapy including QOL in locally advanced urothelial carcinoma remain unclear. The present study evaluated the influence of neoadjuvant platinum-based chemotherapy on QOL in patients with locally advanced urothelial carcinoma.

Methods

Between June 2013 and March 2016, 83 urothelial carcinoma patients who received two courses of neoadjuvant chemotherapy were enrolled in this prospective observational study. Neoadjuvant regimens included gemcitabine + cisplatin (GCis) or gemcitabine + carboplatin (GCb) therapies. As a primary endpoint, we assessed QOL changes in each group before and after chemotherapy using the Quality of Life questionnaire on days 1, 3, and 15 of each cycle. Secondary endpoints included toxicity, safety, weight loss, renal function decline, and tumor responses.

Results

QOL analyses were performed in 39 patients receiving GCis and in 44 patients receiving GCb. Appetite loss, role functioning, nausea/vomiting, physical, and fatigue deteriorated >10% from baseline in the GCis group but not in the GCb group. Constipation worsened, whereas scores for pain and emotional items improved in both groups. Objective response rates were 38.5 and 43.2% in the GCis and GCb groups, respectively.

Conclusions

Both GCis and GCb regimens were feasible in terms of QOL. The GCb regimen may be associated with a better QOL status especially in regard to gastrointestinal symptoms.

Available only for authorised users

Basch E (2014) New frontiers in patient-reported outcomes: adverse event reporting, comparative effectiveness, and quality assessment. Annu Rev Med 65:307–317. doi:10.1146/annurev-med-010713-141500 CrossRefPubMed

Di Maio M, Gallo C, Leighl NB et al (2015) Symptomatic toxicities experienced during anticancer treatment: agreement between patient and physician reporting in three randomized trials. J Clin Oncol 33(8):910–915. doi:10.1200/jco.2014.57.9334 CrossRefPubMed

Dogliotti L, Carteni G, Siena S et al (2007) Gemcitabine plus cisplatin versus gemcitabine plus carboplatin as first-line chemotherapy in advanced transitional cell carcinoma of the urothelium: results of a randomized phase 2 trial. Eur Urol 52(1):134–141. doi:10.1016/j.eururo.2006.12.029 CrossRefPubMed

Bamias A, Lainakis G, Kastritis E et al (2007) Biweekly carboplatin/gemcitabine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: report of efficacy, quality of life and geriatric assessment. Oncology 73(5–6):290–297. doi:10.1159/000132394 CrossRefPubMed

Witjes JA, Comperat E, Cowan NC et al (2014) EAU guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2013 guidelines. Eur Urol 65(4):778–792. doi:10.1016/j.eururo.2013.11.046 CrossRefPubMed

Canter D, Viterbo R, Kutikov A et al (2011) Baseline renal function status limits patient eligibility to receive perioperative chemotherapy for invasive bladder cancer and is minimally affected by radical cystectomy. Urology 77(1):160–165. doi:10.1016/j.urology.2010.03.091 CrossRefPubMed

Koie T, Ohyama C, Hashimoto Y et al (2013) Efficacies and safety of neoadjuvant gemcitabine plus carboplatin followed by immediate cystectomy in patients with muscle-invasive bladder cancer, including those unfit for cisplatin: a prospective single-arm study. Int J Clin Oncol 18(4):724–730. doi:10.1007/s10147-012-0447-z CrossRefPubMed

Ohyama C, Hatakeyama S, Yoneyama T et al (2014) Neoadjuvant chemotherapy with gemcitabine plus carboplatin followed by immediate radical cystectomy for muscle-invasive bladder cancer. Int J Urol 21(1):3–4. doi:10.1111/iju.12230 CrossRefPubMed

Yoneyama T, Tobisawa Y, Yoneyama T et al (2015) Carboplatin-based combination chemotherapy for elderly patients with advanced bladder cancer. Int J Clin Oncol 20(2):369–374. doi:10.1007/s10147-014-0706-2 CrossRefPubMed

10.

Koie T, Ohyama C, Yamamoto H et al (2014) Neoadjuvant gemcitabine and carboplatin followed by immediate cystectomy may be associated with a survival benefit in patients with clinical T2 bladder cancer. Med Oncol 31(5):949. doi:10.1007/s12032-014-0949-9 CrossRefPubMedPubMedCentral

11.

Galsky MD, Hahn NM, Rosenberg J et al (2011) A consensus definition of patients with metastatic urothelial carcinoma who are unfit for cisplatin-based chemotherapy. Lancet Oncol 12(3):211–214CrossRefPubMed

12.

Matsuo S, Imai E, Horio M et al (2009) Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis 53(6):982–992. doi:10.1053/j.ajkd.2008.12.034 CrossRefPubMed

13.

Soga N, Onishi T, Arima K et al (2007) Paclitaxel carboplatin chemotherapy as a second-line chemotherapy for advanced platinum resistant urothelial cancer in Japanese cases. Int J Urol 14(9):828–832. doi:10.1111/j.1442-2042.2007.01831.x CrossRefPubMed

14.

Di Lorenzo G, Buonerba C, Bellelli T et al (2015) Third-line chemotherapy for metastatic urothelial cancer: a retrospective observational study. Medicine 94(51):e2297. doi:10.1097/md.0000000000002297 CrossRefPubMedPubMedCentral

15.

Niegisch G, Retz M, Siener R, Albers P (2016) Quality of life in patients with cisplatin-resistant urothelial cancer: typical ailments and effect of paclitaxel-based salvage therapy. Urol Oncol 34(6):256. doi:10.1016/j.urolonc.2016.02.002 (e215-221) CrossRefPubMed

16.

Park JH, Lee SW, Kim HS et al (2013) Combination of gemcitabine and carboplatin as first line treatment in elderly patients or those unfit for cisplatin-based chemotherapy with advanced transitional cell carcinoma of the urinary tract. Cancer Chemoth Pharmacol 71(4):1033–1039. doi:10.1007/s00280-013-2098-9 CrossRef

17.

Nicholson S (2012) Chemotherapy for bladder cancer in patients with impaired renal function. Nat Rev Urol 9(1):52–57. doi:10.1038/nrurol.2011.176 CrossRef

Title: Quality-of-life evaluation during platinum-based neoadjuvant chemotherapies for urothelial carcinoma
Authors: Ken Fukushi
Takuma Narita
Shingo Hatakeyama
Hayato Yamamoto
Osamu Soma
Teppei Matsumoto
Yuki Tobisawa
Tohru Yoneyama
Atsushi Imai
Takahiro Yoneyama
Yasuhiro Hashimoto
Takuya Koie
Chikara Ohyama
Publication date: 01-04-2017
Publisher: Springer Japan
Published in: International Journal of Clinical Oncology / Issue 2/2017
Print ISSN: 1341-9625
Electronic ISSN: 1437-7772
DOI: https://doi.org/10.1007/s10147-016-1071-0

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 2/2017

Biomarkers for precision medicine in bladder cancer

Feasibility of adjuvant chemotherapy with S-1 plus carboplatin followed by single-agent maintenance therapy with S-1 for completely resected non-small-cell lung cancer: results of the Setouchi Lung Cancer Group Study 1001

Recent progress and perspectives on prostate cancer biomarkers

Clinical outcomes of stage IV colorectal cancer after R0 resection: a multi-institutional retrospective analysis

The effect of consolidation chemotherapy after concurrent chemoradiotherapy on the survival of patients with locally advanced non-small cell lung cancer: a meta-analysis

Diagnostic value of tumor markers for lung adenocarcinoma-associated malignant pleural effusion: a validation study and meta-analysis

Keynote webinar | Spotlight on antibody–drug conjugates in cancer